CUE
NSCCue Biopharma Inc.
Healthcare•Biotechnology
Watchlist:
Last updated: Sunday 6th July 2025
0.70
+0.00 (0.46%)
Prev Close:0.692
Open:0.692
Bid:0.6703
Ask:0.7
52 Week Range
0.451.99
Volume:219,171
Mkt Cap:51 M
42
MarketXLS Rank ®
Hold
Price Target
$0.80
+15.1%
Financials
Financial Statements
CUE - Balance Sheet (Annual)
| Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Invalid date | |
|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 3 M | 4 M | 3 M | 3 M | 2 M | 882666.0 | 2 M | |
| Accumulated Depreciation & Depletion | -4 M | -4 M | -4 M | -3 M | -3 M | -2 M | -1 M | |
| Cash And Equivalents | 22 M | 49 M | 52 M | 64 M | 75 M | 44 M | 21 M | |
| Cash Cash Equivalents And Short Term Investments | 22 M | 49 M | 76 M | 64 M | 85 M | 59 M | 39 M | |
| Cash Equivalents | 39 M | 50068.0 | ||||||
| Common Stock | 62000.0 | 47000.0 | 43000.0 | 32202.0 | 30351.0 | 26562.0 | 20697.0 | |
| Current Accrued Expenses | 3 M | 4 M | 4 M | 5 M | 3 M | 2 M | 2 M | |
| Current Capital Lease Obligation | 4 M | 3 M | 3 M | 5 M | 5 M | 4 M | 4,461 M | |
| Current Deferred Taxes Assets | 1 M | 2 M | 3 M | 3 M | 2 M | 2 M | 140000.0 | |
| Deferred Financing Costs | 142000.0 | 142000.0 | 141748.0 | |||||
| Financial Assets | 3 M | 1 M | ||||||
| Float Term Debt | 1 M | 7 M | 14 M | 5 M | 2 M | |||
| Long Term Capital Lease Obligation | 1 M | 3 M | 6 M | 5 M | 2 M | 1 M | ||
| Long Term Debt And Capital Lease Obligation | 1 M | 7 M | 14 M | 5 M | 2 M | 1 M | ||
| Long Term Provisions | 2 M | 4 M | 5 M | |||||
| Net Other Unrealized Gain Loss | 96000.0 | 7131.0 | 17452.0 | 637.0 | ||||
| Non Current Deferred Taxes Assets | 95 M | 86 M | 73 M | 58 M | 44 M | 31 M | 19 M | |
| Non Current Prepaid Assets | 2 M | 3 M | 3 M | 3 M | 3 M | |||
| Other Current Borrowings | 4 M | 37000.0 | 73967.0 | |||||
| Other Current Liabilities | 85000.0 | 2 M | 645344.0 | 7 M | 4 M | 2 M | ||
| Other Equity Adjustments | 1 M | |||||||
| Payables | 3 M | 4 M | 3 M | 3 M | 2 M | 882666.0 | 2 M | |
| Preferred Stock | 10 M | 10 M | ||||||
| Retained Earnings | -342 M | -301 M | -251 M | -197 M | -153 M | -109 M | -72 M | |
| Total Capitalization | 19 M | 49 M | 88 M | 71 M | 81 M | 55 M | 34 M | |
| Total Equity Gross Minority | 17 M | 37 M | 66 M | 65 M | 79 M | 55 M | 34 M | |
| Total Equity Gross Minority Interest | 17 M | 37 M | 66 M | 65 M | 79 M | 55 M | 34 M | |
| Total Liabilities And Total Equity Gross Minority Interest | 32 M | 62 M | 91 M | 83 M | 100 M | 72 M | 45 M | |
| Total Non Current Liabilities Net Minority Interes | 1 M | 9 M | 14 M | 5 M | 4 M | 5 M | 5 M | |
| Unearned Premiums | -37000.0 | -74000.0 | ||||||
| Working Capital | 11 M | 34 M | 66 M | 56 M | 71 M | 49 M | 34 M | |
| Accrec | 945000.0 | 2 M | 57000.0 | 3 M | 1 M | 754898.0 | ||
| Addpaid | 359 M | 338 M | 316 M | 263 M | 232 M | 163 M | 106 M | |
| Capstk | 62000.0 | 47000.0 | 43000.0 | 32202.0 | 30351.0 | 26562.0 | 20697.0 | |
| Comstkeqty | 17 M | 37 M | 66 M | 65 M | 79 M | 55 M | 34 M | |
| Curdebt | 4 M | 4 M | 2 M | |||||
| Curdebtcaplease | 8 M | 7 M | 5 M | 5 M | 5 M | 4 M | ||
| Curdefliab | 381465.0 | |||||||
| Gainlossnoearn | -10321.0 | -10958.0 | ||||||
| Grosppe | 9 M | 11 M | 15 M | 15 M | 12 M | 7 M | 4 M | |
| Netppe | 5 M | 7 M | 11 M | 12 M | 9 M | 5 M | 3 M | |
| Noncurdefliab | -2000.0 | |||||||
| Othca | 3 M | 3 M | 2 M | 2 M | 2 M | 1 M | 972000.0 | |
| Othnca | 257000.0 | 268000.0 | 278000.0 | 290000.0 | 551667.0 | 823625.0 | 958729.0 | |
| Othncl | 2 M | 3 M | 3 M | 3 M | 3 M | 3 M | ||
| Othprop | 5 M | 7 M | 11 M | 12 M | 9 M | 5 M | ||
| Othrec | 15 M | 3 M | 3 M | 1 M | ||||
| Payacc | 6 M | 8 M | 6 M | 7 M | 5 M | 3 M | 4 M | |
| Prepaid | 2 M | 1 M | 841000.0 | 954792.0 | 1 M | 860107.0 | 1 M | |
| Restcash | 150000.0 | 150000.0 | ||||||
| Totassets | 32 M | 62 M | 91 M | 83 M | 100 M | 72 M | 45 M | |
| Totca | 25 M | 51 M | 77 M | 68 M | 88 M | 61 M | 41 M | |
| Totcl | 14 M | 17 M | 12 M | 13 M | 16 M | 12 M | 6 M | |
| Toteqty | 17 M | 37 M | 66 M | 65 M | 79 M | 55 M | 34 M | |
| Totliab | 15 M | 24 M | 26 M | 18 M | 21 M | 17 M | 11 M | |
| Totnca | 7 M | 10 M | 14 M | 15 M | 12 M | 9 M | 5 M | |
| Totncl | 1 M | 9 M | 14 M | 5 M | 4 M | 5 M | 5 M | |
| Trustpref | 10 M | 10 M |
Call: 1-877-778-8358 
Welcome! I'm Ankur, the founder and CEO of MarketXLS. With more than ten years of experience, I have assisted over 2,500 customers in developing personalized investment research strategies and monitoring systems using Excel.
I invite you to book a demo with me or my team to save time, enhance your investment research, and streamline your workflows.
I invite you to book a demo with me or my team to save time, enhance your investment research, and streamline your workflows.
Implement "your own" investment strategies in Excel with thousands of MarketXLS functions and templates.
MarketXLS provides all the tools I need for in-depth stock analysis. It's user-friendly and constantly improving. A must-have for serious investors.
I have been using MarketXLS for the last 6+ years and they really enhanced the product every year and now in the journey of bringing in AI...
MarketXLS is a powerful tool for financial modeling. It integrates seamlessly with Excel and provides real-time data.
I have used lots of stock and option information services. This is the only one which gives me what I need inside Excel.